Evrofarma SA (EVRr)

Athens

Currency in EUR

2.680

+0.020(+0.75%)

Closed·03/10

Fair Value

Unlock Value

Day's Range

2.660

2.700

52 wk Range

1.330

2.920

EVRr Financial Summary

A brief financial summary of Evrofarma SA as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio13.12

Price/Book1.8

Debt / Equity95.41%

Return on Equity14.44%

Dividend Yield1.87%

EBITDA5.31M

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Income Statement

Total Revenues

aa.aa

33.48

33.91

36.7

45.38

48.76

Gross Profit

aa.aa

6.06

4.99

3.84

5.8

7.06

Operating Income

aa.aa

2.19

1.48

0.23

2.26

3.66

Net Income

aa.aa

0.16

1.06

-0.36

1.42

2.2

Balance Sheet

Total Assets

aa.aa

41.2

46.38

46.52

48.81

47.36

Total Current Liabilities

aa.aa

22.25

10.71

10.2

12.67

13.04

Total Equity

aa.aa

11.87

12.96

12.61

14.03

16.23

Cash Flow

Levered Free Cash Flow

aa.aa

0.8

0.06

-2.44

0.42

0.68

Cash from Operations

aa.aa

1.78

1.46

-0.81

2.64

3.14

Cash from Investing

aa.aa

-0.86

-0.81

-3.27

-1.33

-2.02

Cash from Financing

aa.aa

-1.37

2.35

1.21

-0.12

-1.9

Net Change in Cash

aa.aa

-0.45

-2.86

1.19

-0.78

* In Millions of EUR (except for per share items)

Dividends

Payout Ratio

Payout ratio (TTM)

Earnings retained

EPS 0.20%

Dividend Yield

1.87%

Industry Median 3.76%

Annualised payout

0.05

Paid annually

5-Years Growth

Growth Streak

Unlock

Earnings

Latest Release

Sep 24, 2024

EPS / Forecast

0.10 / --

Revenue / Forecast

21.65M / --

EPS Revisions

Unlock

Last 90 days

FAQ

What were Evrofarma SA's earnings for the latest quarter?

The Evrofarma SA EPS (TTM) is 0.20. Evrofarma SA reported sales of 21.65, net income of 1.40, and EPS of 0.10 for the latest quarter.

What was Evrofarma SA's net income for the latest quarter?

Evrofarma SA's net income for the latest quarter was 1.40.

How did Evrofarma SA's performance compare year-over-year in the latest quarter?

The company's revenue moved from 25.20 in the previous quarter to 21.65 in the latest quarter, and net income moved from 0.79 to 1.40 compared to the previous quarter.

What is Evrofarma SA's net profit margin on a TTM basis?

Evrofarma SA's trailing twelve months (TTM) net profit margin is 4.52%.

How does Evrofarma SA's debt to equity ratio compare to industry standards?

Evrofarma SA's total debt-to-equity ratio is 95.41%.

What is Evrofarma SA's return on investment on a TTM basis?

Evrofarma SA's trailing twelve months (TTM) return on investment (ROI) is 14.44%.

Did Evrofarma SA gain or lose cash last quarter?

In the latest quarter, Evrofarma SA's net change in cash was -0.19 million.

What were Evrofarma SA's total assets and liabilities in the latest quarter?

As of the latest quarter, Evrofarma SA reported total assets of 49.56 million and total liabilities of 13.82 million.

How has Evrofarma SA's total revenue grown this year?

Evrofarma SA's total revenue was 25.20 in the previous quarter and 21.65 in the latest quarter.

What is Evrofarma SA's gross margin on a TTM basis?

Evrofarma SA's trailing twelve months (TTM) gross margin is 20.49%.

What was Evrofarma SA's revenue per share for the latest quarter?

Evrofarma SA's revenue per share for the latest quarter was 61.45.

NSE 30

5,234.97

+16.95

+0.32%

NSE All Share

143,584.05

+604.60

+0.42%

US 30

46,770.00

+249.8

+0.54%

US 500

6,714.10

-1.3

-0.02%

FTSE 100

9,491.25

+63.52

+0.67%

DAX

24,378.80

-43.76

-0.18%

South Africa Top 40

102,696.68

+1,589.61

+1.57%

Market Movers

Name	Last	Chg. %	Vol.
UBA	43.00	0.00%	80.10M
Access Holdings	26.50	+2.71%	71.74M
Guaranty Trust Holding	95.85	-0.05%	35.14M
Zenith Bank	69.40	+0.58%	29.87M
PZ Cussons Nigeria	41.70	+9.88%	21.29M
Nigerian Breweries	76.00	+2.36%	7.72M
Aradel Holdings	650.10	+5.64%	3.84M

Name	Last	Chg. %	Vol.
UAC Of Nigeria	73.70	+10.00%	1.04M
Nigerian Enamelware PLC	42.45	+9.97%	106.22K
Ellah Lakes	13.47	+9.96%	25.95M
PZ Cussons Nigeria	41.70	+9.88%	21.29M
Neimeth	6.75	+9.76%	1.27M
Berger Paints	39.70	+9.67%	381.89K
Austin Laz	3.19	+9.62%	616.79K

Name	Last	Chg. %	Vol.
Julius Berger	122.90	-9.96%	376.37K
Thomaswy	3.24	-9.50%	3.24M
John Holt PLC	7.20	-9.43%	320.99K
Daarcomm	1.03	-6.36%	2.32M
UPDC	6.49	-5.81%	2.63M
Transcorp	47.600	-4.61%	737.83K
International Energy Insurance	2.97	-3.57%	3.14M

Trending Stocks

Name	Last	Chg. %	Vol.
Wema Bank	18.95	+9.54%	11.61M
Ellah Lakes	13.47	+9.96%	25.95M
Betaglas	486.00	0.00%	18.93K
UAC Of Nigeria	73.70	+10.00%	1.04M
UBA	43.00	0.00%	80.10M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaa A	5,379.30	+61.41%	8,682.73
Aaaaaa Aaaaaa	525.10	+39.57%	732.88
Aaa Aaa	1,870.00	+31.28%	2,454.94
A A Aaaaaaaaa	71.00	+18.59%	84.20
Aaaaaaaaaaaaaaa	160.00	+16.70%	186.72
Aaa Aaaa Aa Aaaa Aa	640.00	+10.95%	710.08

Name	Last	Upside	Fair Value
Aaaaa A	5,379.30	+61.41%	8,682.73
Aaaaaa Aaaaaa	525.10	+39.57%	732.88
Aaa Aaa	1,870.00	+31.28%	2,454.94
A A Aaaaaaaaa	71.00	+18.59%	84.20
Aaaaaaaaaaaaaaa	160.00	+16.70%	186.72
Aaa Aaaa Aa Aaaa Aa	640.00	+10.95%	710.08

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Evrofarma SA (EVRr)

EVRr Financial Summary

Key Ratios

Statements Highlights

Dividends

Earnings

FAQ

What were Evrofarma SA's earnings for the latest quarter?

What was Evrofarma SA's net income for the latest quarter?

How did Evrofarma SA's performance compare year-over-year in the latest quarter?

What is Evrofarma SA's net profit margin on a TTM basis?

How does Evrofarma SA's debt to equity ratio compare to industry standards?

What is Evrofarma SA's return on investment on a TTM basis?

Did Evrofarma SA gain or lose cash last quarter?

What were Evrofarma SA's total assets and liabilities in the latest quarter?

How has Evrofarma SA's total revenue grown this year?

What is Evrofarma SA's gross margin on a TTM basis?

What was Evrofarma SA's revenue per share for the latest quarter?

Trending Stocks